The first randomised controlled trial on microdosing LSD for ADHD has revealed that the approach does not significantly improve symptoms when compared to a placebo. The findings challenge popular beliefs surrounding the effectiveness of LSD microdosing for ADHD treatment in managing attention and focus issues.

The study, conducted by Matthias Liechti and his colleagues at the University of Basel in Switzerland, involved 53 adult participants with moderate to severe ADHD. Over six weeks, half were given 20-microgram doses of LSD twice weekly, while the rest received a placebo. ADHD symptoms were monitored using a 54-point scale. Results showed symptom scores dropped by 7 points for those taking LSD and 9 points for those on placebo. The lack of significant difference suggests the psychedelic was no more effective than the placebo for alleviating ADHD symptoms.

These findings counter the growing trend of microdosing psychedelics to enhance focus and well-being without hallucinations. While some observational studies have reported improvements in ADHD symptoms, this trial underscores the need for rigorous evidence. Researchers are now exploring whether daily doses or different methods of administration could yield results akin to conventional ADHD medicines.

Conor Murray from the University of California, Los Angeles, pointed out that further investigations are required to establish whether acute dosing could have any direct impact on symptoms. Until robust findings confirm otherwise, relying on microdosing as an ADHD treatment remains speculative at best.

Source: New Scientist